ArticlePediatric nephrology (Berlin, Germany)2010
Beneficial effect of cinacalcet in a child with familial hypocalciuric hypercalcemia.
Article in Pediatric nephrology (Berlin, Germany), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 62 citations in OpenAlex.
- Genetic variants predisposing to an increased risk of kidney stone disease.The Journal of clinical investigation · 2025Article
- Case report: Clinical and genetic characteristics of heterozygous CaSR variants in three Chinese females with familial hypocalciuric hypercalcemia type 1: a report of three cases.Frontiers in genetics · 2025Article
- Disorders of the Calcium Sensing Signaling Pathway: From Familial Hypocalciuric Hypercalcemia (FHH) to Life Threatening Conditions in Infancy.Journal of clinical medicine · 2022Review
- Genetic causes of neonatal and infantile hypercalcaemia.Pediatric nephrology (Berlin, Germany) · 2022Review
- Off-label use of cinacalcet in pediatric primary hyperparathyroidism: A French multicenter experience.Frontiers in pediatrics · 2022Article
- Severe Symptomatic Hypercalcemia in a Patient With Familial Hypocalciuric Hypercalcemia.Cureus · 2021Article
- Therapeutic Opportunities of Targeting Allosteric Binding Sites on the Calcium-Sensing Receptor.ACS pharmacology & translational science · 2021Review
- Rare diseases caused by abnormal calcium sensing and signalling.Endocrine · 2021Review
- International Union of Basic and Clinical Pharmacology. CVIII. Calcium-Sensing Receptor Nomenclature, Pharmacology, and Function.Pharmacological reviews · 2020Review
- Use of calcimimetics in children with normal kidney function.Pediatric nephrology (Berlin, Germany) · 2019Review
- Cinacalcet as rescue therapy for refractory hyperparathyroidism in young children with advanced chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2019Article
- Calcimimetic and calcilytic therapies for inherited disorders of the calcium-sensing receptor signalling pathway.British journal of pharmacology · 2018Review
- Hypercalcemia: a consultant's approach.Pediatric nephrology (Berlin, Germany) · 2018Review
- Vitamin D-Resistant Rickets and Cinacalcet-One More Favorable Experience.Frontiers in pediatrics · 2018Article
- Cinacalcet as adjunctive therapy in pseudohypoparathyroidism type 1b.Pediatric nephrology (Berlin, Germany) · 2016Article
- The calcium-sensing receptor in bone--mechanistic and therapeutic insights.Nature reviews. Endocrinology · 2015Review
- Minireview: the intimate link between calcium sensing receptor trafficking and signaling: implications for disorders of calcium homeostasis.Molecular endocrinology (Baltimore, Md.) · 2012Review
- Familial hypocalciuric hypercalcemia: new mutation in the CASR gene converting valine 697 to methionine.European journal of pediatrics · 2012Article
- Clinical and biochemical outcomes of cinacalcet treatment of familial hypocalciuric hypercalcemia: a case series.Journal of medical case reports · 2011Article
- Role of Cinacalcet in Treating Cardiac Dysfunction Secondary to Hyperparathyroidism: A Case Series.Indian journal of nephrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe a child with familial hypocalciuric hypercalcemia (FHH) in whom the hypercalcemia seemed to interfere with tissue healing after tympanoplasty. Consequently, he was placed on cinacalcet (30 mg/day), changed after 2 weeks to 60 mg/day. The treatment resulted in a decrease in serum parathyroid hormone (PTH) from 148 to 32 pg/mL (normal 7-75) and ionized calcium from 1.48 to 1.23 mmol/L (1.13-1.34), as well as successful healing of the revised surgical scar. Over the 12-month treatment period no complications were noted. We conclude that cinacalcet may be considered a new, and currently the only, tool in treating children with symptomatic FHH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.